18 results on '"Mikhail Byakhov"'
Search Results
2. Abstract CT113: Preliminary data on a phase 1b, first-in-human study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with refractory metastatic gastric cancer
- Author
-
N. S. Besova, Elena Artamonova, Kristina A. Novoselova, Vladimir Moiseyenko, Liubov Yu Vladimirova, Natalia Trenina, Margarita Suetina, Sergei Tjulandin, Ilya Tsimafeyeu, Vyacheslav Kurakin, Galina Statsenko, Mikhail Byakhov, Alina Kashanova, Ekaterina Obarevich, Natalia А. Abramova, and Anastasia Mochalova
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,Anemia ,Nausea ,Cancer ,medicine.disease ,Gastroenterology ,Hyperphosphatemia ,Oncology ,Pharmacokinetics ,Internal medicine ,medicine ,Clinical endpoint ,medicine.symptom ,Hyponatremia ,business ,Adverse effect - Abstract
Fibroblast growth factor receptor 2 (FGFR2) is associated with an unfavorable prognosis in patients with gastric cancer. Acquired mutations in FGFR2 develop resistance to multikinase inhibitors. Besides, resistance to monoclonal antibodies depends on the type of FGFR2 isoforms IIIc or IIIb expressed by cancer cells. Alofanib (RPT835) is a small molecule, allosteric inhibitor that binds to the non-active site of FGFR2 extracellular domain. RPT835GC1B (NCT04071184) is an ongoing Phase 1b open-label study evaluating the safety and preliminary efficacy of alofanib in patients with metastatic gastric adenocarcinoma pretreated with ≥ 1 previous lines of therapy. The standard dose-escalation part (design 3+3) aims to establish the maximum tolerated dose (MTD) or recommended phase 2 dose (R2PD) as a primary endpoint. The first part of the study includes a 28-day period when alofanib is administered daily intravenously for 5-days followed by a 2-day interval (rest). There are five dose levels: 50, 100, 165, 250, and 350 mg/m2. Secondary endpoints include pharmacokinetic (PK) parameters, rate of adverse events, progression-free survival (PFS), overall survival (OS), and objective response rate. All patients received alofanib until disease progression or unacceptable toxicity. As of data cutoff on December 30, 2020, 13 patients have been enrolled in the trial. Patients were predominantly male (85%), 54% had 2 and more metastatic sites, including liver metastases (54%), and were heavily pretreated (60% received previous 3-6 lines of therapy). To date, all enrolled patients have been studied for safety and have not experienced any dose-limiting toxicities (DLTs) within the 28-day DLT-assessment window. Grade 3 or higher drug related adverse events have included raised ALT/AST at 50 mg/m2, diarrhea at 165 mg/m2, and hyponatremia at 350 mg/m2. 93% of patients had any grade adverse events. Most common Grade 1-2 adverse events included fatigue, diarrhea, nausea, anemia, thrombocytopenia, increased alkaline phosphatase, and reactions immediately after intravenous injections (facial flushing, dizziness, weakness, sweating, and sinus tachycardia). Grade 1 hyperphosphatemia was founded in 25% of cases. One patient discontinued treatment due to drug related Grade 3 uncontrolled diarrhea. Alofanib has demonstrated evidence of biologic activity in 12 patients in the first 4 dose levels evaluated to date. Disease control rate was 75% (1 durable partial response (13 months) at 50 mg/m2 and 8 stable diseases at 50-250 mg/m2). After a median follow-up of 4.5 months, the median PFS and OS was not reached. In conclusion, dosing up to 350 mg/m2 of alofanib was well tolerated, DLT and MTD were not reached. The early biologic activity of alofanib in the late-line treatment of metastatic gastric cancer is encouraging. In addition to the above, any updated safety, PK, and efficacy data will be presented at the time of the AACR meeting. Citation Format: Ilya Tsimafeyeu, Galina Statsenko, Anastasia Mochalova, Natalia Trenina, Vyacheslav Kurakin, Natalia Besova, Kristina Novoselova, Natalia Abramova, Ekaterina Obarevich, Alina Kashanova, Margarita Suetina, Vladimir Moiseyenko, Mikhail Byakhov, Elena Artamonova, Liubov Vladimirova, Sergei Tjulandin. Preliminary data on a phase 1b, first-in-human study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with refractory metastatic gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr CT113.
- Published
- 2021
3. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer
- Author
-
N. Azarnia, José Baselga, Alexey Manikhas, Vladimir Semiglazov, Clifford A. Hudis, R.H. Goldfarb, S. Forenza, M. Rozencweig, Javier Cortes, J. Matera, Mikhail Byakhov, L Roman, D. Lokanatha, and Antonio Llombart
- Subjects
Oncology ,medicine.medical_specialty ,Paclitaxel ,Receptor, ErbB-2 ,Liposomal Doxorubicin ,Breast Neoplasms ,Antibodies, Monoclonal, Humanized ,Disease-Free Survival ,Drug Administration Schedule ,Polyethylene Glycols ,chemistry.chemical_compound ,Breast cancer ,Trastuzumab ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Humans ,Doxorubicin ,Progression-free survival ,Prospective Studies ,Neoplasm Metastasis ,skin and connective tissue diseases ,Cardiotoxicity ,Antibiotics, Antineoplastic ,business.industry ,Hematology ,Original Articles ,medicine.disease ,Metastatic breast cancer ,Corrigenda ,Antineoplastic Agents, Phytogenic ,Treatment Outcome ,chemistry ,cardiovascular system ,Female ,business ,medicine.drug - Abstract
Nonpegylated liposomal doxorubicin liposomal doxorubicin, (Myocet™; Sopherion Therapeutics, Inc Canada, and Cephalon, Europe) (NPLD; Myocet(®)) in combination with trastuzumabHerceptin(®) (Hoffmann-La Roche) has shown promising activity and cardiac safety. We conducted a randomized phase III trial of first-line NPLD plus trastuzumab and paclitaxel (Pharmachemie B.V.) (MTP) versus trastuzumab plus paclitaxel (TP) in patients with human epidermal growth factor 2 receptor (HER2)-positive metastatic breast cancer.Patients were randomly assigned to NPLD (M, 50 mg/m(2) every 3 weeks for six cycles), trastuzumab (T, 4 mg/kg loading dose followed by 2 mg/kg weekly), and paclitaxel (P, 80 mg/m(2) weekly) or T + P at the same doses until progression or toxicity. The primary efficacy outcome was progression-free survival (PFS).One hundred and eighty-one patients were allocated to receive MTP, and 183 to TP. Median PFS was 16.1 and 14.5 months with MTP and TP, respectively [hazard ratio (HR) 0.84; two-sided P = 0.174]. In patients with estrogen receptor (ER)- and progesterone receptor (PR)-negative tumors, PFS was 20.7 and 14.0 months, respectively [HR 0.68; 95% confidence interval (CI) 0.47-0.99]. Median overall survival (OS) was 33.6 and 28.9 months with MTP and TP, respectively (HR 0.79; two-sided P = 0.083). In ER- and PR-negative tumors, OS was 38.2 and 27.9 months, respectively (HR 0.63; 95% CI 0.42-0.93). The frequency of adverse events was higher with MTP, but there was no significant difference in cardiac toxicity between treatment arms.The trial failed to demonstrate a significant clinical improvement with the addition of M to TP regimen. The clinical benefit observed in an exploratory analysis in the ER- and PR-negative population deserves consideration for further clinical trials.NCT00294996.
- Published
- 2019
4. Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models
- Author
-
Evgenia Stepanova, Jean-Baptiste Joose, Frits Daeyaert, Ilya Tsimafeyeu, Nina Peretolchina, Dmitry Khochenkov, Koen Van Akene, Sergei Tjulandin, Eliso Solomko, Oxana Ryabaya, Mikhail Byakhov, Wei Yin, and John H. Ludes-Meyers
- Subjects
0301 basic medicine ,Cancer Research ,Bevacizumab ,Angiogenesis ,Angiogenesis Inhibitors ,Antineoplastic Agents ,Pharmacology ,Biology ,Benzoates ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Cell Movement ,Cell Line, Tumor ,Human Umbilical Vein Endothelial Cells ,medicine ,Animals ,Humans ,Molecular Targeted Therapy ,Receptor, Fibroblast Growth Factor, Type 2 ,IC50 ,Cell Proliferation ,Sulfonamides ,Cell growth ,Fibroblast growth factor receptor 2 ,Endothelial Cells ,medicine.disease ,Xenograft Model Antitumor Assays ,Disease Models, Animal ,030104 developmental biology ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Cancer cell ,Growth inhibition ,Ovarian cancer ,medicine.drug - Abstract
Alofanib (RPT835) is a novel selective allosteric inhibitor of fibroblast growth factor receptor 2 (FGFR2). We showed previously that alofanib could bind to the extracellular domain of FGFR2 and has an inhibitory effect on FGF2-induced phoshphorylation of FRS2α. In the present study, we further showed that alofanib inhibited phosphorylation of FRS2α with the half maximal inhibitory concentration (IC50) values of 7 and 9 nmol/l in cancer cells expressing different FGFR2 isoforms. In a panel of four cell lines representing several tumour types (triple-negative breast cancer, melanoma, and ovarian cancer), alofanib inhibited FGF-mediated proliferation with 50% growth inhibition (GI50) values of 16-370 nmol/l. Alofanib dose dependently inhibited the proliferation and migration of human and mouse endothelial cells (GI50 11-58 nmol/l) compared with brivanib and bevacizumab. Treatment with alofanib ablated experimental FGF-induced angiogenesis in vivo. In a FGFR-driven human tumour xenograft model, oral administration of alofanib was well tolerated and resulted in potent antitumour activity. Importantly, alofanib was effective in FGFR2-expressing models. These results show that alofanib is a potent FGFR2 inhibitor and provide strong rationale for its evaluation in patients with FGFR2-driven cancers.
- Published
- 2016
5. FGFR2 inhibition could suppress spermatogenesis
- Author
-
Vadim A. Kashuro, Olga A. Vakunenkova, Sergei Tjulandin, Mikhail Rozhko, Nataliya V. Lapina, Mikhail Byakhov, Anastasia Skorobogatova, Evgenia Gavrilova, Kira Stosman, Marina V. Melikhova, Ilya Tsimafeyeu, and Nadezhda Dragun
- Subjects
Cancer Research ,Oncology ,business.industry ,Incidence (epidemiology) ,Medicine ,Physiology ,Cancer ,Reproductive age ,business ,medicine.disease ,Spermatogenesis ,Male Reproductive Tract - Abstract
e15659 Background: The incidence of cancer among the people of reproductive age is constantly increasing. Although FGF2/FGFR2 expression in the male reproductive tract has been reported, there is no evidence of the impact of FGFRs inhibitors on sperm function. Therefore, the objective of this large study was to determine the effects of alofanib, selective FGFR2 allosteric extracellular inhibitor on the regulation of sperm physiology using the rat and rabbit models. Methods: Two-hundred forty Sprague-Dawley rats and 30 Chinchilla white rabbits received alofanib (0–40.5 and 0–21.6 mg/kg/day, respectively) intravenously on a consecutive daily dosing schedule for six months. Eighty rats and 8 rabbits were in the control group. The subchronic study evaluated high doses (300 mg/kg/day) of alofanib for 2 months in 15 male rats. Necropsy was conducted following treatment/recovery periods, and histologic examinations were performed. Results: Animals were active. After injections of a dose equivalent to a human therapeutic dose during 6 months, most of the seminiferous tubules were empty, the elements of spermatogenesis were not classified, and altered primary spermatogonia and spermatocytes were distinguished in male rats. After injections of a five-fold dose, all seminiferous tubules were empty and expelled by a cylindrical epithelium. Very similar changes in sperm physiology were founded in rabbits. Most of the seminiferous tubules were blank, and some tubules contained eosinophilic amorphous masses. High doses of alofanib resulted in pronounced atrophy of the spermatogenic tubule epithelium. Multinucleated giant cells were observed in the lumen of a part of the tubules. There were no changes in untreated animals. Conclusions: FGFR2 inhibition led to the suppression of spermatogenesis. Male cancer patients should be informed of this potential adverse event before treatment with FGFR2 inhibitors.
- Published
- 2020
6. Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies
- Author
-
Koen Jeanne Alfons Van Aken, Evgenia Stepanova, Eliso Solomko, Mikhail Byakhov, Wei Yin, Frits Daeyaert, Alexandra Tyulyandina, Evgenia Gavrilova, Ilya Tsimafeyeu, Jean-Baptiste Joos, Daniel Harrison, Sergei Tjulandin, Dmitry Kochenkov, and Nina Peretolchina
- Subjects
0301 basic medicine ,endocrine system diseases ,Paclitaxel ,Cell Survival ,medicine.medical_treatment ,Mice, Nude ,Antineoplastic Agents ,Pharmacology ,Biology ,Benzoates ,Carboplatin ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,In vivo ,Cell Line, Tumor ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Animals ,Humans ,Receptor, Fibroblast Growth Factor, Type 3 ,Pharmacology (medical) ,Receptor, Fibroblast Growth Factor, Type 1 ,Receptor, Fibroblast Growth Factor, Type 2 ,Protein Kinase Inhibitors ,Cell Proliferation ,Ovarian Neoplasms ,Chemotherapy ,Sulfonamides ,Neovascularization, Pathologic ,Cell growth ,medicine.disease ,Tumor Burden ,030104 developmental biology ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Cancer cell ,Tumor necrosis factor alpha ,Female ,Ovarian cancer - Abstract
Purpose Early data suggest that combining FGFR2 inhibitors with platinum-containing cytotoxic agents for the treatment of epithelial ovarian cancer may yield increased antitumor activity. We investigated antitumor activity of alofanib (RPT835), a novel allosteric FGFR2 inhibitor, in ovarian cancer in vitro and in vivo. Methods Equal amounts of ovarian cancer cell (SKOV3) lysates were analyzed for FGFR1–3 protein expression using Wes. To assess the efficacy of alofanib on FGF-mediated cell proliferation, SKOV3 cells were incubated and were treated with serially diluted alofanib. Basic FGF was added at a concentration of 25 ng/ml. Control wells were left untreated. Cell growth inhibition was determined using Promega’s Cell Titer-Glo® assay. Immunocompromised mice were used for xenotransplantation of SKOV3 cancer cells. Seventy animals with measurable tumors were selected on day 10 and randomized into control groups (no treatment or chemotherapy alone (paclitaxel + carboplatin) and treatment groups (alofanib orally or intravenously (different dose levels) in combination with chemotherapy). Measurements of tumor volume (mm3) were performed by digital calipers every 3 days during 31 days after tumor inoculation. Number of tumor vessels and Ki-67 index were calculated. Results SKOV3 cells express FGFR1 and FGFR2 but not FGFR3. Basic FGF increased proliferation of the ovarian cancer cells in untreated control group (P = 0.001). Alofanib inhibited growth of FGFR2-expressing SKOV3 cells with GI50 value of 0.37 μmol/L. Treatment with alofanib in combination with paclitaxel/carboplatin resulted in tumor growth delay phenotype in all treatment groups compared to control non-treatment groups. Compound exhibited a dose-dependent effect on tumor growth. Daily intravenous regimen of alofanib (total maximum dose per week was 350 mg/kg) demonstrated significant effect (inhibiting growth by 80 % and by 53 % in comparison with vehicle and chemotherapy group alone, respectively (P
- Published
- 2016
7. 151O Preclinical characterization of alofanib, a novel allosteric FGFR2 inhibitor
- Author
-
H. Tsimafeyeu, E. Stepanova, Genoveva Murillo, Sergei Tjulandin, D. Khochenkov, Mikhail Byakhov, E. Gavrilova, and N. Lapina
- Subjects
0301 basic medicine ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,business.industry ,030220 oncology & carcinogenesis ,Allosteric regulation ,Medicine ,Hematology ,Computational biology ,business - Published
- 2016
8. Abstract B084: Preclinical pharmacokinetic evaluation of alofanib for cancer treatment
- Author
-
Vlatka Bencetić Mihaljević, Genoveva Murillo, Jasna Padovan, Sergei Tjulandin, Evgenia Gavrilova, Mikhail Byakhov, Ilya Tsimafeyeu, and Nadezhda Dragun
- Subjects
Cancer Research ,business.industry ,Cancer ,Tail vein ,Pharmacology ,medicine.disease ,Oral gavage ,Cancer treatment ,Bioavailability ,Oncology ,Pharmacokinetics ,Oral administration ,Medicine ,Dosing ,business - Abstract
Alofanib (RPT835) is a novel allosteric FGFR2 inhibitor with activity in FGFR2-expressing cancers. Here we explore the pharmacokinetic (PK) profile of compound. Five preclinical PK studies were conducted. In Study 1, alofanib was administered to 49 male BALB/C mice via two routes (oral and iv). Mice in group 1 received a single iv injection of the alofanib (30 mg/kg), while mice in group 2 received a single dose (30 mg/kg) via oral gavage. The aim of Study 2 was to evaluate the PK in 24 male Sprague Dawley rats after a single iv dose of 22 mg/kg and oral dosing in capsules at three dose levels (22, 110, and 220 mg/kg). In Study 3, PK of pharmaceutical form of alofanib in male Sprague Dawley rats after a single iv dose of 55.3, 113.8 and 218.7 mg/kg was evaluated. Studies 4 and 5 compared PK profile for alofanib in male Sprague Dawley rats after a single intraduodenal (i.d.) and subcutaneous (s.c.) dosing at 29 and 145 mg/kg. Six animals per dose group were dosed, with plasma samples collected from the tail vein up to 24 hours. Plasma concentrations were quantified by LC-MS/MS using a research qualified method. The PK data are summarized in Table. StudyGroup(dose, mg/kg)C0/Cmax,ng/mlTmax,ht1/2AUC,h*ng/mLCL,mL/min/kgVss,L/kgF,%1iv, 3057739-0.93580386.76.9NCoral/gavage, 3043.61-2NCNANCNCNC2iv, 2279323-0.441423427.10.47-oral/caps, 2222.02.0NC68.0--0.36oral/caps, 11082.32.5NC1.0--0.18oral/caps, 220110.01.0NC1.0--0.183iv, 55.3246499-0.863710523.80.3-iv, 113.8432342-0.7313078814.80.29-iv, 218.7730496-0.6836314510.10.26-4i.d, 29360.5NC116---i.d, 145980.5NC188---5s.c, 2975130.50.9817218---s.c, 145373000.51.7855020--- NC - Parameter cannot be calculated Following oral administration, alofanib appeared rapidly in plasma but could not be detected after 2 hours. Bioavailability for oral administration is estimated to be low ( Citation Format: Ilya Tsimafeyeu, Mikhail Byakhov, Vlatka Bencetić Mihaljević, Jasna Padovan, Genoveva Murillo, Nadezhda Dragun, Evgenia Gavrilova, Sergei Tjulandin. Preclinical pharmacokinetic evaluation of alofanib for cancer treatment [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B084.
- Published
- 2018
9. Molecular Modeling, de novo Design and Synthesis of a Novel, Extracellular Binding Fibroblast Growth Factor Receptor 2 Inhibitor Alofanib (RPT835)
- Author
-
Koen Jeanne Alfons Van Aken, Ilya Tsimafeyeu, Frits Daeyaert, Mikhail Byakhov, Jean-Baptiste Joos, John H. Ludes-Meyers, and Sergei Tjulandin
- Subjects
0301 basic medicine ,Angiogenesis ,Allosteric regulation ,Antineoplastic Agents ,Biology ,Fibroblast growth factor ,Benzoates ,03 medical and health sciences ,Structure-Activity Relationship ,Allosteric Regulation ,Cell Line, Tumor ,Drug Discovery ,Structure–activity relationship ,Humans ,Receptor, Fibroblast Growth Factor, Type 2 ,Receptor ,Genetics ,Sulfonamides ,Fibroblast growth factor receptor 2 ,Ligand (biochemistry) ,Cell biology ,Molecular Docking Simulation ,030104 developmental biology ,Models, Chemical ,Fibroblast growth factor receptor ,Drug Screening Assays, Antitumor - Abstract
Background: Fibroblast growth factor (FGF) receptors (FGFRs) play a key role in tumor growth and angiogenesis. The present report describes our search for an extracellularly binding FGFR inhibitor using a combined molecular modeling and de novo design strategy. Methods: Based upon crystal structures of the receptor with its native ligand and knowledge of inhibiting peptides, we have developed a computational protocol that predicts the putative binding of a molecule to the extracellular domains of the receptor. This protocol, or scoring function, was used in combination with the de novo synthesis program 'SYNOPSIS' to generate high scoring and synthetically accessible compounds. Results: Eight compounds belonging to 3 separate chemical classes were synthesized. One of these compounds, alofanib (RPT835), was found to be an effective inhibitor of the FGF/FGFR2 pathway. The preclinical in vitro data support an allosteric inhibition mechanism of RPT835. RPT835 potently inhibited growth of KATO III gastric cancer cells expressing FGFR2, with GI50 value of 10 nmol/L. Conclusion: These results provide strong rationale for the evaluation of compound in advanced cancers.
- Published
- 2015
10. Corrigendum to ‘Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models’ [Eur J Cancer 61 (2016) 20–28]
- Author
-
Wei Yin, Nina Peretolchina, Evgenia Stepanova, Mikhail Byakhov, Eliso Solomko, Oxana Ryabaya, Koen Van Akene, Jean-Baptiste Joose, John H. Ludes-Meyers, Frits Daeyaert, Dmitry Khochenkov, Sergei Tjulandin, and Ilya Tsimafeyeu
- Subjects
Cancer Research ,Oncology ,business.industry ,Cancer research ,Medicine ,Cancer ,business ,medicine.disease - Published
- 2017
11. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
- Author
-
Domenico Magazzu, José Baselga, Mikhail Byakhov, Federico Vazquez, Vladimir Semiglazov, Bozhok Aa, Milvia Zambetti, Ana Lluch, Sergei Tjulandin, Jutta Steinseifer, Mauro Mansutti, Luca Gianni, Dominik Heinzmann, Pinuccia Valagussa, Belén Ojeda, Wolfgang Eiermann, Angela Moliterni, Mikhail Lichinitser, Miguel Angel Climent, and Eva Ciruelos
- Subjects
Oncology ,Adult ,medicine.medical_specialty ,medicine.medical_treatment ,Antineoplastic Agents ,Breast Neoplasms ,Kaplan-Meier Estimate ,Antibodies, Monoclonal, Humanized ,Inflammatory breast cancer ,Disease-Free Survival ,law.invention ,Breast cancer ,Randomized controlled trial ,law ,Trastuzumab ,Internal medicine ,medicine ,Clinical endpoint ,Humans ,skin and connective tissue diseases ,neoplasms ,Neoadjuvant therapy ,Aged ,Proportional Hazards Models ,business.industry ,Hazard ratio ,Genes, erbB-2 ,Middle Aged ,medicine.disease ,Neoadjuvant Therapy ,Clinical trial ,Treatment Outcome ,Chemotherapy, Adjuvant ,Female ,Inflammatory Breast Neoplasms ,business ,medicine.drug ,Follow-Up Studies - Abstract
Summary Background In our randomised, controlled, phase 3 trial NeOAdjuvant Herceptin (NOAH) trial in women with HER2-positive locally advanced or inflammatory breast cancer, neoadjuvant trastuzumab significantly improved pathological complete response rate and event-free survival. We report updated results from our primary analysis to establish the long-term benefit of trastuzumab-containing neoadjuvant therapy. Methods We did this multicentre, open-label, randomised trial in women with HER2-positive locally advanced or inflammatory breast cancer. Participants were randomly assigned (1:1), by computer program with a minimisation technique, to receive neoadjuvant chemotherapy alone or with 1 year of trastuzumab (concurrently with neoadjuvant chemotherapy and continued after surgery). A parallel group with HER2-negative disease was included and received neoadjuvant chemotherapy alone. Our primary endpoint was event-free survival. Analysis was by intention to treat. This study is registered at www.controlled-trials.com, ISRCTN86043495. Findings Between June 20, 2002, and Dec 12, 2005, we enrolled 235 patients with HER2-positive disease, of whom 118 received chemotherapy alone and 117 received chemotherapy plus trastuzumab. 99 additional patients with HER2-negative disease were included in the parallel cohort. After a median follow-up of 5·4 years (IQR 3·1–6·8) the event-free-survival benefit from the addition of trastuzumab to chemotherapy was maintained in patients with HER2-positive disease. 5 year event-free survival was 58% (95% CI 48–66) in patients in the trastuzumab group and 43% (34–52) in those in the chemotherapy group; the unadjusted hazard ratio (HR) for event-free survival between the two randomised HER2-positive treatment groups was 0·64 (95% CI 0·44–0·93; two-sided log-rank p=0·016). Event-free survival was strongly associated with pathological complete remission in patients given trastuzumab. Of the 68 patients with a pathological complete response (45 with trastuzumab and 23 with chemotherapy alone), the HR for event-free survival between those with and without trastuzumab was 0·29 (95% CI 0·11–0·78). During follow-up only four cardiovascular adverse events were regarded by the investigator to be drug-related (grade 2 lymphostasis and grade 2 lymphoedema, each in one patient in the trastuzumab group, and grade 2 thrombosis and grade 2 deep vein thrombosis, each in one patient in the chemotherapy-alone group). Interpretation These results show a sustained benefit in event-free survival from trastuzumab-containing neoadjuvant therapy followed by adjuvant trastuzumab in patients with locally advanced or inflammatory breast cancer, and provide new insight into the association between pathological complete remission and long-term outcomes in HER2-positive disease. Funding F Hoffmann-La Roche.
- Published
- 2014
12. Abstract B146: Preclinical pharmacokinetic studies of RPT835, an allosteric FGFR2 inhibitor
- Author
-
Jasna Padovan, Mikhail Byakhov, Ilya Tsimafeyeu, Sergei Tjulandin, Vlatka Bencetić Mihaljević, and Genoveva Murillo
- Subjects
Cancer Research ,business.industry ,Allosteric regulation ,Cancer ,Pharmacology ,medicine.disease ,Bioavailability ,Oncology ,Pharmacokinetics ,Oral administration ,Dose group ,Sprague dawley rats ,medicine ,Dosing ,business - Abstract
RPT835 (recommended INN, alofanib) is a novel allosteric FGFR2 inhibitor with activity in FGFR2-expressing women's cancers. Administration of RPT835 intravenously (iv) daily demonstrated dramatic effect in ovarian cancer xenografts compared with RPT835 orally daily [S. Tjulandin et al. AACR 2015]. Here we explore the pharmacokinetic (PK) profile of RPT835. Three preclinical PK studies were conducted. In Study 1, RPT835 was administered to 49 male BALB/C mice via two routes (oral and iv). Mice in group 1 received a single iv injection of the RPT835 (30 mg/kg), while mice in group 2 received a single dose of RPT835 (30 mg/kg) via oral gavage. The aim of the Study 2 was to evaluate the PK for RPT835 in 24 male Sprague Dawley rats after a single iv dose of 22 mg/kg and oral dosing in capsules at three dose levels (22, 110 and 220 mg/kg). In Study 3, PK of pharmaceutical form of RPT835 in male Sprague Dawley rats after a single iv dose of 55.3, 113.8 and 218.7 mg/kg was evaluated. Six animals per dose group were dosed, with plasma samples collected from the tail vein up to 24 hours. Plasma concentrations were quantified by LC-MS/MS using a research qualified method. The PK data are summarized in Table. Following oral administration, RPT835 appeared rapidly in plasma (within 30 min), but could not be detected after 2 hours. Bioavailability for oral administration could not be calculated but is estimated to be low ( PK resultsStudyGroup (dose, mg/kg)C0/Cmax, ng/mlTmax, ht1/2AUC, h*ng/mLCL, mL/min/kgVss, L/kgF, %1iv, 3057739-0.93580386.76.9NC - Parameter cannot be calculatedoral/gavage, 3043.61-2NCNCNCNCNC2iv, 2279323-0.441423427.10.47-oral/caps, 2222.02.0NC68.0--0.36oral/caps, 11082.32.5NC1.0--0.18oral/caps, 220110.01.0NC1.0--0.183iv, 55.3246499-0.863710523.80.3-iv, 113.8432342-0.7313078814.80.29-iv, 218.7730496-0.6836314510.10.26- Citation Format: Ilya Tsimafeyeu, Mikhail Byakhov, Vlatka Bencetić Mihaljević, Jasna Padovan, Genoveva Murillo, Sergei Tjulandin. Preclinical pharmacokinetic studies of RPT835, an allosteric FGFR2 inhibitor. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B146.
- Published
- 2015
13. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer
- Author
-
Gianni Bonadonna, Wolfgang Eiermann, José Baselga, Bozhok Aa, Antonio Llombart Cussac, Vincente Guillem Porta, Mikhail Byakhov, Pinuccia Valagussa, Mauro Mansutti, Milvia Zambetti, Luca Gianni, Aňa Lluch, Vladimir Semiglazov, Dolores Sabadell, Angel Martinez-Agulló, Günther Raab, JJ López, and Marco Greco
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Cyclophosphamide ,Anthracycline ,Paclitaxel ,medicine.drug_class ,medicine.medical_treatment ,Breast Neoplasms ,Kaplan-Meier Estimate ,Antimetabolite ,chemistry.chemical_compound ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Humans ,Doxorubicin ,Chemotherapy ,business.industry ,Surgery ,Regimen ,Methotrexate ,chemistry ,Fluorouracil ,Chemotherapy, Adjuvant ,Female ,business ,medicine.drug - Abstract
Purpose To evaluate the addition of paclitaxel to an anthracycline-based adjuvant regimen and to compare this combination with the same regimen given as primary systemic (neoadjuvant) therapy. Patients and Methods A total of 1,355 women with operable breast cancer were randomly assigned to one of three treatments: surgery followed by adjuvant doxorubicin (75 mg/m2) followed by cyclophosphamide, methotrexate, and fluorouracil (CMF; arm A); surgery followed by adjuvant paclitaxel (200 mg/m2) plus doxorubicin (60 mg/m2), followed by CMF (arm B); or paclitaxel (200 mg/m2) plus doxorubicin (60 mg/m2) followed by CMF followed by surgery (arm C). The two coprimary objectives were to assess the effects on relapse-free survival (RFS) of the addition of paclitaxel to postoperative chemotherapy (arm B v arm A) and primary chemotherapy versus adjuvant chemotherapy (arm B v arm C). Results Doxorubicin plus paclitaxel followed by CMF was well-tolerated as adjuvant or as primary chemotherapy. The addition of paclitaxel to adjuvant doxorubicin followed by CMF significantly improved RFS compared with adjuvant doxorubicin alone followed by CMF (hazard ratio [HR], 0.73; P = .03). Distant RFS was similarly improved (HR, 0.70; P = .027). There was no significant difference in RFS when the paclitaxel/doxorubicin/CMF chemotherapy was given before surgery compared with the same regimen given after surgery (HR, 1.21; P = .18). However, the rate of breast-conserving surgery was significantly higher with preoperative chemotherapy (63% v 34%; P < .001). Conclusion Incorporating paclitaxel into anthracycline-based adjuvant therapy resulted in a significant improvement in RFS and distant RFS. When given as primary systemic therapy, the paclitaxel-containing regimen allowed breast-sparing surgery in a significant percentage of patients.
- Published
- 2009
14. Abstract 796: Alofanib, a novel allosteric FGFR2 inhibitor, shows potent antitumor activity in ovarian cancer with FGFR2 expression
- Author
-
Evgenia Stepanova, Ilya Tsimafeyeu, Sergei Tjulandin, Daniel Harrison, D. A. Khochenkov, and Mikhail Byakhov
- Subjects
Cancer Research ,Chemotherapy ,Cell growth ,business.industry ,medicine.medical_treatment ,Cancer ,Pharmacology ,medicine.disease ,Carboplatin ,chemistry.chemical_compound ,Breast cancer ,Oncology ,chemistry ,Paclitaxel ,medicine ,Growth inhibition ,Ovarian cancer ,business - Abstract
Alofanib (formerly known as RPT835) is a novel allosteric FGFR2 inhibitor with activity in FGFR2-expressing triple-negative breast cancer [Tjulandin S, et al. San Antonio Breast Cancer Symposium 2014]. Early data suggest that combining FGFR2 inhibitors with platinum-containing cytotoxic agents for the treatment of epithelial ovarian cancer may yield increased antitumor activity [Cole C, et al. Cancer Biol Ther. 2010]. We investigated antitumor activity of alofanib in ovarian cancer in vitro and in vivo. To assess the efficacy of alofanib on FGF-mediated cell proliferation, ovarian cancer (SKOV-3) FGFR2-expressing cells were incubated in a 96-well microculture plate and were treated with serially diluted RPT835. Basic FGF was added at a concentration of 25 ng/ml. Control wells were left untreated. Cell growth inhibition was determined using Promega's Cell Titer-Glo® assay. Immunocompromised mice were used for xenotransplantation of FGFR2 high-expressing ovarian cancer cells (SCOV-3). Seventy animals with measurable tumors were selected on day 10 and randomized into control groups (no treatment or chemotherapy alone (paclitaxel + carboplatin) and treatment groups (alofanib orally or intravenously (different dose levels) in combination with chemotherapy). Measurements of tumor volume (mm3) were performed by digital calipers every 3 days during 30 days after tumor inoculation. Basic FGF significantly increased proliferation of the ovarian cancer cells in untreated control group (P = 0.001). Alofanib treatment resulted in growth inhibition of SKOV-3 cell line in vitro. Treatment of alofanib in combination with paclitaxel/carboplatin demonstrated significant tumor growth delay phenotype in all treatment groups compared to control non-treatment groups. Alofanib exhibited a dose-dependent effect on tumor growth. Daily intravenous regimen of alofanib (total maximum dose per week was 350 mg/kg) demonstrated dramatic effect (inhibiting growth by 80% and by 53% in comparison with vehicle and chemotherapy group alone, respectively (P These results provide strong rationale for evaluation of alofanib in combination with paclitaxel and carboplatin in patients with ovarian cancer. Citation Format: Sergei Tjulandin, Mikhail Byakhov, Evgenia Stepanova, Dmitry Khochenkov, Daniel Harrison, Ilya Tsimafeyeu. Alofanib, a novel allosteric FGFR2 inhibitor, shows potent antitumor activity in ovarian cancer with FGFR2 expression. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 796. doi:10.1158/1538-7445.AM2015-796
- Published
- 2015
15. 476 FGFR2 targeting with allosteric inhibitor RPT835
- Author
-
Sergey Tjulandin, Frits Daeyaert, Mikhail Byakhov, John H. Ludes-Meyers, Wei Yin, and Ilya Tsimafeyeu
- Subjects
Cancer Research ,Oncology ,Chemistry ,Allosteric regulation ,Pharmacology - Published
- 2014
16. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy
- Author
-
JJ López, Milvia Zambetti, Ana Lluch, Mikhail Byakhov, Marco Greco, Gianni Bonadonna, José Baselga, Günther Raab, Angel Martinez-Agulló, Vicente Guillem Porta, Dolores Sabadell, Vladimir Semiglazov, Luca Gianni, Mauro Mansutti, Antonio Llombart Cussac, Bozhok Aa, Wolfgang Eiermann, and Pinuccia Valagussa
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Cyclophosphamide ,Paclitaxel ,medicine.drug_class ,Breast Neoplasms ,Pharmacology ,Antimetabolite ,chemistry.chemical_compound ,Breast cancer ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Preoperative Care ,medicine ,Humans ,Doxorubicin ,Aged ,Aged, 80 and over ,business.industry ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Methotrexate ,Treatment Outcome ,Tolerability ,chemistry ,Fluorouracil ,Multivariate Analysis ,Female ,business ,medicine.drug - Abstract
Purpose: The European Cooperative Trial in Operable breast cancer (ECTO) randomly tested whether efficacy of adjuvant doxorubicin followed by i.v. cyclophosphamide, methotrexate, and fluorouracil (CMF; doxorubicin → CMF, arm A) could be improved by adding paclitaxel (doxorubicin/paclitaxel → CMF) as adjuvant (arm B) or primary systemic therapy (PST, arm C). We report here feasibility, tolerability, locoregional antitumor activity, and breast conservation rate. Methods: A total of 1,355 women entered the study. Feasibility and safety were compared in arm A versus arms B plus C. Surgical findings were compared in arms A plus B versus arm C. Results: Grade 3 or 4 National Cancer Institute toxicities were low ( Conclusions: Doxorubicin/paclitaxel → CMF is feasible, safe, and well tolerated. Given as PST, it is markedly active, allowing for breast-sparing surgery in a large fraction of patients.
- Published
- 2005
17. Freedom from progression (FFP) by adding paclitaxel (T) to doxorubicin (A) followed by CMF as adjuvant or primary systemic therapy: 10-yr results of a randomized phase III European Cooperative Trial in Operable Breast Cancer (ECTO)
- Author
-
José Baselga, Gianni Bonadonna, Gabriella Mariani, Hernán Cortés-Funes, Vladimir Semiglazov, Wolfgang Eiermann, Angela Moliterni, Dolores Sabadell, Vicente Guillem, Domenico Magazzu, Belén Ojeda, Luca Gianni, Mikhail Byakhov, Tadeusz Pienkowski, Marian Colozza, Bozhok Aa, Milvia Zambetti, Ana Lluch, Pinuccia Valagussa, and Mauro Mansutti
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,medicine.disease ,Systemic therapy ,Metastatic breast cancer ,chemistry.chemical_compound ,Breast cancer ,Docetaxel ,Paclitaxel ,chemistry ,Internal medicine ,Freedom from progression ,medicine ,Doxorubicin ,business ,Adjuvant ,medicine.drug - Abstract
537 Background: At the time the ECTO was designed in 1996, taxanes were only indicated for patients with metastatic breast cancer. However, paclitaxel and docetaxel were still to be tested in the adjuvant setting. In addition there was relatively scarce information on the comparative efficacy of neoadjuvant and adjuvant regimens. The ECTO trial was designed to evaluate the addition of paclitaxel to an anthracycline-based adjuvant regimen and to compare this combination with the same regimen given as primary systemic (neoadjuvant) therapy. Methods: A total of 1,355 women with operable breast cancer were randomized to one of three treatments: 1) surgery followed by adjuvant single agent doxorubicin (A) followed by CMF (arm A); 2) surgery followed by adjuvant paclitaxel plus doxorubicin (AT) followed by CMF (arm B); 3) AT followed by CMF followed by surgery (arm C). The two co-primary objectives were to assess the effects on freedom from progression (FFP) of: 1) the addition of paclitaxel to post-operative chemotherapy (arm B versus arm A); and 2) primary versus adjuvant chemotherapy (arm B versus arm C). Results: At 10 years, in the adjuvant setting FFP remained statistically significant in favor of AT followed by CMF (arm B, HR 0.77, P=0.045). Distant FFP was similarly improved but overall survival was not (HR 0.82, P=0.24). There was no significant difference in FFP when chemotherapy was given after surgery compared with the same regimen given before surgery (arm B vs arm C, HR 0.79, P=0.07). In the primary chemotherapy arm, patients who achieved a pathological complete remission (pCR) had improved distant FFP (P < 0.001) compared to patients who did not achieve pCR. When given as primary systemic therapy, the paclitaxel-containing regimen allowed breast-sparing surgery in a significant percentage of patients, which did not translate in an increased risk of ipsilateral breast recurrence compared to the risk observed in patients in the adjuvant arms. Conclusions: Incorporating paclitaxel into anthracycline-based adjuvant therapy resulted in a significantly improved FFP and DFFP.
- Published
- 2013
18. Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer
- Author
-
Mauro Mansutti, Eva Ciruelos, Federico Vazquez, Wolfgang Eiermann, José Baselga, Pinuccia Valagussa, Sergei Tjulandin, Mikhail Byakhov, Vladimir Semiglazov, Mikhail Lichinitser, Domenico Magazzu, Jutta Steinseifer, Bozhok Aa, Alexey Manikhas, Milvia Zambetti, Ana Lluch, Belén Ojeda, Luca Gianni, and Miguel Angel Climent
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Chemotherapy ,Randomization ,Cyclophosphamide ,business.industry ,medicine.medical_treatment ,medicine.disease ,Chemotherapy regimen ,Inflammatory breast cancer ,Breast cancer ,Trastuzumab ,Internal medicine ,Medicine ,Doxorubicin ,business ,medicine.drug - Abstract
503 Background: The monoclonal antibody trastuzumab (H) has been shown to improve event-free survival (EFS) and pathologic complete response (pCR) in patients with HER2-positive locally advanced or inflammatory breast cancer receiving neoadjuvant chemotherapy with or without one year of trastuzumab in the primary analysis of the NOAH study (Gianni L, Lancet 2010). Updated EFS and overall survival (OS) results are now presented. Methods: In this international, multicenter, open-label, randomized phase III trial patients with locally advanced or inflammatory breast cancer were randomized 1:1 to receive CT+H followed by adjuvant H versus CT alone. A parallel cohort of 99 comparable patients with HER2-negative disease was included and treated with the same chemotherapy regimen. The neoadjuvant chemotherapy regimen included doxorubicin, paclitaxel, cyclophosphamide, methotrexate and 5-fluorouracil. The primary objective was to compare EFS defined as time from randomization to disease recurrence or progression [local, regional, distant or contralateral] or death due to any cause). Results: After a median follow up of 5.4 years, the EFS benefit with trastuzumab was confirmed. Cardiac tolerability was good despite concurrent administration of trastuzumab with doxorubicin. Two patients (2%) developed reversible symptomatic congestive heart failure and are presently alive. Conclusions: Present analysis confirms the significant EFS benefit observed in the primary analysis of the NOAH study, and shows a strong trend towards improved OS with the addition of trastuzumab to chemotherapy. pCR rate may be considered as a possible primary endpoint and early indicator of benefit in future neoadjuvant studies of HER2-targeted agents. Clinical trial information: 86043495. [Table: see text]
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.